The newest COPD medication approved by the FDA is Ohtuvayre (ensifentrine), which gained approval on June 26, 2024. It’s not actually a pill, though. Ensifentrine is an inhaled treatment delivered through a nebulizer, and it works in a way no previous inhaled COPD medication has: it combines two mechanisms in a single drug, both opening the airways and reducing inflammation. If you’ve heard buzz about a “new pill” for COPD, this is almost certainly what people are referring to, and it represents the first new class of inhaled COPD treatment in over two decades.
Why It’s Called a New Class of Treatment
Most inhaled COPD medications fall into familiar categories: long-acting bronchodilators that relax airway muscles, or inhaled corticosteroids that tamp down inflammation. Ensifentrine does something different. It blocks two specific enzymes, PDE3 and PDE4, that normally break down signaling molecules your cells use to keep airways relaxed and inflammation in check. By blocking both enzymes at once, the drug has a dual effect: it relaxes the smooth muscle lining your airways (making it easier to breathe) and dials down the inflammatory activity that drives COPD flare-ups.
There is an older oral pill for COPD called roflumilast (brand name Daliresp) that blocks PDE4 alone. Roflumilast has been available for years and is taken by mouth, which may be why some people associate “new COPD treatment” with a pill. Ensifentrine is different because it adds PDE3 inhibition on top of PDE4 inhibition, and because it’s inhaled directly into the lungs rather than swallowed.
How You Take It
Ensifentrine comes as a liquid in small single-use ampules. You pour the contents into a standard jet nebulizer, attach the mouthpiece, and inhale the mist. Each session takes roughly five to seven minutes, and you do it twice a day. The dose is 3 mg per session. It’s designed for home use, so you don’t need to visit a clinic for treatments.
If you’re already comfortable with a nebulizer, the routine will feel familiar. If you’ve only ever used handheld inhalers, there’s a learning curve, but it’s straightforward. Your provider will want to confirm you’re using correct technique before starting.
How Well It Works
In pooled clinical trial data covering more than 1,500 patients, ensifentrine cut the rate of moderate to severe COPD flare-ups by 41% compared to placebo. It also significantly extended the time before a patient experienced their first exacerbation. These results held across a broad range of patients, including those already taking other long-acting bronchodilators or inhaled corticosteroids. About 62% of trial participants were on at least one other maintenance inhaler, and 18% were also using an inhaled corticosteroid, so the benefit came on top of existing therapy rather than replacing it.
Side Effects Compared to Older Options
One of the most notable things about ensifentrine is its safety profile. In meta-analyses pooling data from multiple trials, the rate of side effects in people taking ensifentrine was essentially the same as in those taking a placebo. That’s a meaningful contrast to roflumilast, the oral PDE4 inhibitor, which is well known for causing nausea, diarrhea, weight loss, and sleep disturbances that lead many patients to stop taking it.
Because ensifentrine is inhaled rather than swallowed, less of it circulates through the rest of your body, which likely explains the milder side effect profile. That said, prescribers are advised to discuss the possibility of mood changes, depression, anxiety, and suicidal thoughts, since PDE4 inhibition has been linked to psychiatric effects with the oral form. These risks appear to be lower with the inhaled route, but they haven’t been ruled out entirely.
Who Is a Candidate
Ensifentrine is FDA-approved for the maintenance treatment of COPD in adults. In practice, guidelines and insurance criteria position it as an add-on therapy rather than a first-line treatment. The 2025 GOLD report, which sets the global standard for COPD management, recommends adding ensifentrine when a patient is already on two long-acting bronchodilators but still experiences shortness of breath.
Some health systems, like the VA, have more specific requirements: moderate to severe COPD confirmed by lung function testing, at least three months on maximal inhaler therapy, at least two moderate flare-ups (or one hospitalization) in the past year, and a documented trial of roflumilast or azithromycin that either failed or wasn’t tolerable. Private insurers vary, but most cover ensifentrine under pharmacy benefits for commercial, Medicare Advantage, and Medicaid plans. Medicare Part D coverage is less consistent, so it’s worth checking with your plan.
What About an Actual Oral Pill?
If you were specifically hoping for a new pill you swallow, the closest option on the horizon is tanimilast, another PDE4 inhibitor being studied as a potential improvement over roflumilast. The goal is better tolerability, meaning fewer of the gut-related side effects that make roflumilast hard to stick with. However, tanimilast has not yet completed Phase 3 trials and is not available for prescription. Roflumilast remains the only oral PDE4 inhibitor currently approved for COPD.
The other major new COPD treatment approved alongside ensifentrine in recent guidelines is dupilumab, a biologic injection (not a pill) for a specific subset of patients: those with high blood eosinophil counts, chronic bronchitis symptoms, and ongoing exacerbations despite being on triple inhaler therapy. It’s given by injection, similar to biologics used in severe asthma.
What to Expect if You Start Ensifentrine
The twice-daily nebulizer sessions add about 10 to 15 minutes total to your daily routine. Because the drug works through both bronchodilation and anti-inflammatory pathways, you may notice easier breathing relatively quickly, while the reduction in flare-ups builds over weeks to months of consistent use. You’ll continue your existing inhalers. Ensifentrine is designed to layer on top of your current regimen, not replace any part of it.
Your provider will likely schedule a follow-up after a few months to assess whether your breathing symptoms and exacerbation frequency have improved. If you’ve been struggling with persistent shortness of breath despite being on two or more inhalers, ensifentrine is the first genuinely new option in a long time worth discussing at your next visit.